drugset / Trial / NCT06063018
RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
There is currently no standardized treatment for patients who have undergone first-line standard treatment. In this study, We investigated the efficacy and safty of RC48 combined with Tislelizumab in the second-line treatment of patients with HER2 expression in recurrent cervical cancer.
Timeline
- Start
- 2023-08-16
- Primary completion
- 2025-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 600 mg | Intravenous |